Published in Ann Neurol on May 01, 2004
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol (2012) 3.07
Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med (2014) 2.68
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med (2011) 1.65
Immune surveillance in the central nervous system. Nat Neurosci (2012) 1.63
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev (2008) 1.52
Pro-cognitive properties of T cells. Nat Rev Immunol (2012) 1.50
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. J Immunol (2007) 1.37
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol (2009) 1.29
Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods (2009) 1.29
Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol (2010) 1.25
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One (2013) 1.21
The role of dendritic cells in CNS autoimmunity. J Mol Med (Berl) (2010) 1.19
Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J Neurosci (2009) 1.16
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem (2012) 1.13
Lymphoid chemokines in the CNS. J Neuroimmunol (2010) 1.07
Role of dendritic cells in differential susceptibility to viral demyelinating disease. PLoS Pathog (2007) 1.04
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology (2012) 1.04
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta (2010) 1.00
Progressive multiple sclerosis. Semin Immunopathol (2009) 1.00
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res (2011) 0.98
Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis. PLoS Pathog (2011) 0.93
Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. PLoS One (2012) 0.93
Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers. Front Cell Neurosci (2014) 0.92
After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream. Am J Pathol (2008) 0.92
G protein-coupled receptors as therapeutic targets for multiple sclerosis. Cell Res (2012) 0.90
Multiple Sclerosis and T Lymphocytes: An Entangled Story. J Neuroimmune Pharmacol (2015) 0.89
Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. Exp Mol Pathol (2007) 0.86
Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.86
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther (2014) 0.85
Myeloid dendritic cells frequencies are increased in children with autism spectrum disorder and associated with amygdala volume and repetitive behaviors. Brain Behav Immun (2012) 0.85
Expression of CCR7 and CD45RA in CD4+ and CD8+ subsets in cerebrospinal fluid of 134 patients with inflammatory and non-inflammatory neurological diseases. J Neuroimmunol (2012) 0.84
Role of C-C chemokine receptor type 7 and its ligands during neuroinflammation. J Neuroinflammation (2012) 0.84
Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx (2005) 0.83
The double-edged sword of autoimmunity: lessons from multiple sclerosis. Toxins (Basel) (2010) 0.83
The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker. PLoS One (2012) 0.82
Dendritic cell migration in health and disease. Nat Rev Immunol (2016) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Autoimmunity, dendritic cells and relevance for Parkinson's disease. J Neural Transm (Vienna) (2012) 0.81
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology (2015) 0.81
Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta. J Neuroimmunol (2010) 0.80
Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. Adv Exp Med Biol (2012) 0.80
Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2013) 0.80
CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. Eur J Immunol (2016) 0.79
Circulating CCR7+ICOS+ Memory T Follicular Helper Cells in Patients with Multiple Sclerosis. PLoS One (2015) 0.79
Novel therapies for memory cells in autoimmune diseases. Clin Exp Immunol (2015) 0.79
T-Lymphocytes Traffic into the Brain across the Blood-CSF Barrier: Evidence Using a Reconstituted Choroid Plexus Epithelium. PLoS One (2016) 0.79
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice. Br J Pharmacol (2014) 0.78
Central Nervous System and Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple Sclerosis. Arch Immunol Ther Exp (Warsz) (2015) 0.78
Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. Front Immunol (2016) 0.77
Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders. Mediators Inflamm (2016) 0.77
Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clin Lipidol (2011) 0.77
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opin Ther Pat (2010) 0.76
T cell responses in the central nervous system. Nat Rev Immunol (2017) 0.76
Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Res Hum Retroviruses (2016) 0.76
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy. Sci Rep (2016) 0.75
In vivo modification of tRNA with an artificial nucleobase leads to full disease remission in an animal model of multiple sclerosis. Nucleic Acids Res (2017) 0.75
MIP-3β/CCL19 is associated with the intrathecal invasion of mononuclear cells in neuroinflammatory and non-neuroinflammatory CNS diseases in dogs. BMC Vet Res (2014) 0.75
CCR7 deficient inflammatory Dendritic Cells are retained in the Central Nervous System. Sci Rep (2017) 0.75
Helminth Immunomodulation in Autoimmune Disease. Front Immunol (2017) 0.75
Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Interferon-β regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis. Immunology (2017) 0.75
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Intra- and interspecific variation in primate gene expression patterns. Science (2002) 7.92
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 5.84
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 3.53
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One (2010) 3.24
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron (2008) 2.44
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum (2007) 2.42
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet (2006) 2.34
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging (2010) 2.32
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med (2009) 2.13
Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc (2006) 2.08
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
The role of nitric oxide in multiple sclerosis. Lancet Neurol (2002) 2.00
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol (2011) 1.98
The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2011) 1.96
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
Natalizumab and PML. Nat Neurosci (2005) 1.85
Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun (2012) 1.82
NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain (2012) 1.82
G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood (2011) 1.82
Demyelination versus remyelination in progressive multiple sclerosis. Brain (2010) 1.82
Oligodendrocytes: biology and pathology. Acta Neuropathol (2009) 1.81
Mitochondrial changes within axons in multiple sclerosis. Brain (2009) 1.81
Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci (2002) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol (2007) 1.78
Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp Neurol (2011) 1.77
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci (2005) 1.74
Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One (2010) 1.73
The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 1.73
Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia (2006) 1.72
Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol (2002) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol (2002) 1.70
Mitochondrial defects in acute multiple sclerosis lesions. Brain (2008) 1.69
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain (2011) 1.68
Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem (2005) 1.67
Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med (2004) 1.67
CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci (2010) 1.65
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain (2011) 1.63